Quick Takeaways
- Paul Bisaro has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,862,088.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Paul Bisaro
- Location
- Parsippany, NJ
- Summary
- The estimated net worth of Paul Bisaro is at least $2,862,088 dollars as of 14 May 2026. Paul Bisaro is the Director of Zoetis Inc. and owns shares of Zoetis Inc. (ZTS) stock worth about $2.11M. Paul Bisaro is the Director of Keenova Therapeutics plc and owns shares of Keenova Therapeutics plc stock worth about $370.8K. Paul Bisaro is the Director of MYRIAD GENETICS INC and owns shares of MYRIAD GENETICS INC (MYGN) stock worth about $359.1K. Paul Bisaro is the Director of TherapeuticsMD, Inc. and owns shares of TherapeuticsMD, Inc. (TXMD) stock worth about $18.2K.
- Signature
- By: Justin Hunter For: Paul Bisaro
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Paul Bisaro and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Zoetis Inc. ($2,114,029).
- Past-year value change for that position: +$151,750.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Paul Bisaro
ZTS
Forms 3/4/5
Zoetis Inc.
- Relationship
- Director
- Holdings value
- $2,114,029
- Past year net change
- +$151,750
- Change %
- +7.7%
- Report period
- 13 May 2026
No ticker
Forms 3/4/5
Keenova Therapeutics plc
- Relationship
- Director
- Holdings value
- $370,798
- Past year net change
- Change %
- Report period
- 23 Feb 2026
MYGN
Forms 3/4/5
MYRIAD GENETICS INC
- Relationship
- Director
- Holdings value
- $359,070
- Past year net change
- +$27,638
- Change %
- +8.3%
- Report period
- 14 May 2026
TXMD
Forms 3/4/5
TherapeuticsMD, Inc.
- Relationship
- Director
- Holdings value
- $18,191
- Past year net change
- Change %
- Report period
- 29 Sep 2022
Insider Transactions Reported by Paul Bisaro:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.